A Pilot Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

Trial Profile

A Pilot Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma

Suspended
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Gemcitabine; Oxaliplatin; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 30 Jun 2023 to 31 Mar 2020.
    • 09 Apr 2018 Planned primary completion date changed from 28 Feb 2020 to 31 Mar 2020.
    • 09 Apr 2018 Status changed from not yet recruiting to suspended as Pending amendment to update correlatives.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top